LIVE WEBINAR: Federal Healthcare Fraud Laws Take Center Stage – Are Lab Sales & Marketing Practices At Risk Now?

$195.00

Wednesday March, 27 2019
2:00 – 3:15 pm ET

Category:

Description

A new anti-kickback law applied to all payers may inadvertently jeopardize the way labs compensate sales personnel, even as increased en- forcement under false claims and Stark mandates have combined to raise a tangled web of compli- ance issues for clinical and AP labs.

In enacting the Eliminating Kickbacks in Recovery Act of 2018 (EKRA), Congress has unwittingly approved an unprecedented expansion of federal anti-kickback liability to private-pay referrals. Intended to address the Nation’s opioid crisis, EKRA enables the government to monitor provider arrangements intended to generate business for any laboratory service, not only those related to individuals in treatment for substance abuse disorders, paid by a federal healthcare program or commercial health insurer.

Meantime, labs and AP groups continue to run afoul of existing fraud and abuse prohibitions which, taken together with modifications to the physician self-referral rule plus the prospect of future changes to the Stark law, create a climate where heightened compliance vigilance is a necessity.

SPEAKER PANEL

S. Craig Holden

S. Craig Holden

Shareholder, Baker Donelson

Dana Simonds

Dana Simonds

Chief Compliance & Ethics Officer, Inform Diagnostics

Jane Pine Wood

Jane Pine Wood

Chief Legal Counsel, BioReference Laboratories

Dennis Weissman

Dennis Weissman

President, Dennis Weissman Associates, LLC

Here’s just a sample of critical questions we’ll answer as part of this “must-attend” 75-minute interactive session:

t

What are the main provisions of EKRA and how do they impact clinical and AP labs?

t

Will Congress move to amend EKRA in 2019 and what should labs do until they act?

t

How is one AP lab company moving to instill a culture of compliance a er settling false claims and kickback allegations?

t

What are the key take-aways for labs in light of recent federal fraud settlements?

t

How were Stark regulations modified under the 2019 Physician Fee Schedule rule?

t

What are the most common compliance violations that put labs at risk?

t

Why is CMS seeking public input on making changes to the Stark law?

t

Can AP labs expect any change in the Stark in-office-ancillary services exception?

t

Do lab whistleblower cases provide a roadmap of problematic practices to avoid?

t

What’s the experts’ take on your questions about EKRA, anti-kickback & Stark laws?